ClinicalTrials.gg
Status unknownNCT02089126Updated Mar 17, 2014

Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes

A Phase 3 interventional study of Gemigliptin/Glimepiride combination in Type 2 Diabetes Mellitus, sponsored by LG Life Sciences. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2014-03-17.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2014), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. gemigliptin · Diabetes Mellitus, Type 2.

Planned enrollment
7th of 18
230 · median 130
Started
2014
with 4 others
Phase 3
9 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
8 of 18
LG Life Sciences

Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, this one is the 7th largest by planned enrollment, is one of 5 that started in 2014, is one of 9 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About gemigliptin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The study objective is to demonstrate the superiority and safety of the combination therapy (as a fix-dose combination) with Gemigliptin and Glimepiride, compared to the Glimepiride monotherapy in patients with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with type 2 diabetes
  2. Adults who are at least 19 years old
  3. Patients who have taken Glimepiride at a stable dose (≥4mg/day) for 8 weeks or more before Visit 1 (screening) as monotherapy or Patients who have taken Glimepiride at a stable dose (≥4mg/day) and Metformin for 8 weeks or more before Visit 1 (screening) as combination therapy
  4. Patients who satisfy the following (%) criteria: 7 ≤ HbA1c ≤ 11
  5. Patients who have been provided an explanation about the objective, method, effects, etc. of the clinical trial and whose form has been signed by himself/herself or his/her representative
  6. Patients who fall under one of the following 3 cases

    1. Patients who are surgically sterile
    2. females who are above 45 years of age and 2 years after the last menstruation
    3. Fertile premenopausal female patients or male patients without having a surgical sterilization, who have agreed to use at least two methods (one of the barrier methods must be included) for up to 14 days after the administration of the last product to avoid pregnancy.

Exclusion criteria

Exclusion Criteria:

  1. Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma
  2. Patients with gestational diabetes or secondary diabetes
  3. Patients with Class III, IV congestive heart failure or arrhythmias requiring treatment
  4. Patients with thyroid gland dysfunction and TSH that is out of normal range
  5. Patients with pituitary insufficiency or adrenal insufficiency
  6. Patients with hereditary problems, such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
  7. Female patients who are pregnant or breastfeeding
  8. Patients whose exceeds 40 kg/m2
  9. Patients whose is below 30mL/min/1.73m2
  10. Patients whose level exceeds 1.5 times the and whose /AST level exceeds 2.5 times the upper limit of the normal range
  11. Patients who are continuously taking the following drugs for 2 weeks or more at Visit 1 (screening), or need to take them continuously and repeatedly

    • cyclosporin, sirolimus, tacrolimus, nicotinic acid (≥1500mg/day), isotretinoin
    • Strong inducers: rifampicin (rifampin), phenytoin, carbamazepine, rifabutin, phenobarbital
    • warfarin, dicoumarin, digoxin
    • systemic
  12. Patients who have taken anti-obesity drugs or had a surgery related to obesity within 12 weeks before Visit 1 (screening)
  13. Patients who have received insulin and GLP-1 analogue treatment within 8 weeks prior to Visit 1 (screening)
  14. Patients who have received a treatment due to malignant tumor within 5years before Visit 1 (screening) However, patients whose basal cell or squamous cell skin cancer or in situ cervical cancer has been treated can be enrolled.
  15. Patients with a history of myocardial infarction, unstable angina and coronary artery bypass surgery within 6 months prior to Visit 1 (screening)
  16. Patients with a history of alcohol or drug addiction within 1 year prior to Visit 1 (screening)
  17. Patients who have a medical history of to the same class as Gemigliptin or dipeptidyl peptidase 4 (DPP 4) inhibitor drugs
  18. Patients with a history of hypersensitivity to the drugs belonging to the same class as Glimepiride or sulfonylureas and sulfonamide
  19. Patients who have participated in another clinical trial within 3 months prior to Visit 1 (screening)
  20. Patients deemed unsuitable for this trial based on the judgment of the investigator
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Gemigliptin/Glimepiride combination

    Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination \& Placebo for Glimepiride.

    Drug: Gemigliptin/Glimepiride combination

  • Placebo comparator
    Placebo

    The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination \& Glimepiride.

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c Changes

    Time frame: Week 0, Week 24

07

Study locations

1 site
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014 and a primary completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2014
First posted
Mar 17, 2014
Start
Jun 2014
Primary completionEst.
Sep 2016
Last update
Mar 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02089126
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Mar 17, 2014
Start date
Jun 2014
Primary completion
Sep 2016 (estimated)
Last update
Mar 17, 2014

Study contacts

Jong Hee Jin
Contact
jonghee@lgls.com
82-2-6924-3122

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemigliptin · Glimepiride

Start the discussion